Literature DB >> 19556728

Nifedipine interferes with migration of vascular smooth muscle cells via inhibition of Pyk2-Src axis.

Nwe Nwe Soe1, Takafumi Ishida, Mari Ishida, Mariko Sawano, Keiko Abe, Narimasa Miho, Kazuaki Chayama, Yasuki Kihara, Masao Yoshizumi.   

Abstract

AIM: Calcium channel blockers (CCBs) inhibit the migration of vascular smooth muscle cells (VSMC) by mechanisms that remain poorly understood. The purpose of the present study was to characterize the signaling mechanisms by which CCBs inhibit VSMC migration. METHODS AND
RESULTS: Nifedipine potently inhibited platelet-derived growth factor (PDGF)-induced chemotaxis, collagen I-induced haptotaxis, and wound-induced migration of human aortic VSMC. In addition, nifedipine inhibited PDGF-induced membrane ruffling and lamellipodium formation. PDGF-induced VSMC migration was significantly inhibited by PP2, a selective inhibitor of the Src kinase family, and was also significantly inhibited by the expression of kinase-inactive Src, suggesting that Src is required for VSMC migration. Nifedipine also inhibited PDGF-induced Src activation (by 60+/-4% with 30 microM) and tyrosinephosphorylation of Cas, paxillin, and cortactin, which are actin-associated substrates of Src. RNA interference-induced knockdown of the Ca(2+)-dependent tyrosine kinase, Pyk2, resulted in inhibition of PDGF-induced Src activation and migration. Finally, nifedipine inhibited PDGF-induced Pyk2 activation in a dose-dependent manner.
CONCLUSION: These data suggest that nifedipine interferes with VSMC migration via inhibition of the Pyk2-Src axis and inhibition of actin remodeling processes, including membrane ruffling and lamellipodium formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556728     DOI: 10.5551/jat.e422

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  6 in total

1.  Cytoskeletal rearrangement and Src and PI-3K-dependent Akt activation control GABA(B)R-mediated chemotaxis.

Authors:  Madhavi J Rane; Jon B Klein; Michelle T Barati; Janice Scherzer; Rui Wu
Journal:  Cell Signal       Date:  2015-02-26       Impact factor: 4.315

2.  Pyk2 activation triggers epidermal growth factor receptor signaling and cell motility after wounding sheets of epithelial cells.

Authors:  Ethan R Block; Michael A Tolino; Jes K Klarlund
Journal:  J Biol Chem       Date:  2010-03-09       Impact factor: 5.157

3.  Recruitment of Pyk2 to SHPS-1 signaling complex is required for IGF-I-dependent mitogenic signaling in vascular smooth muscle cells.

Authors:  Xinchun Shen; Gang Xi; Yashwanth Radhakrishnan; David R Clemmons
Journal:  Cell Mol Life Sci       Date:  2010-06-03       Impact factor: 9.261

Review 4.  Clinical roles of calcium channel blockers in ischemic heart diseases.

Authors:  Daisuke Sueta; Noriaki Tabata; Seiji Hokimoto
Journal:  Hypertens Res       Date:  2017-01-26       Impact factor: 3.872

5.  Hematopoietic Pyk2 regulates migration of differentiated HL-60 cells.

Authors:  Lin Wang; Jonathan Learoyd; Yingli Duan; Alan R Leff; Xiangdong Zhu
Journal:  J Inflamm (Lond)       Date:  2010-05-27       Impact factor: 4.981

6.  Osteoprotegerin Prevents Development of Abdominal Aortic Aneurysms.

Authors:  Batmunkh Bumdelger; Hiroki Kokubo; Ryo Kamata; Masayuki Fujii; Koichi Yoshimura; Hiroki Aoki; Yuichi Orita; Takafumi Ishida; Megu Ohtaki; Masataka Nagao; Mari Ishida; Masao Yoshizumi
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.